SGLT2 – Medxy AI

What’s New in the ADA 2024 Standards of Care: Practical Guidance on Weight‑Lowering Drugs, Cardiorenal Protection, and Technology for Diabetes

By MedXY 09/26/2025

The ADA 2024 Standards update care pathways for diabetes with stronger guidance on obesity pharmacotherapy (GLP‑1/GIP agents), earlier use of SGLT2/GLP‑1 for cardiorenal benefit, and expanded technology recommendations.

Diabetes & Endocrinology news Specialties

What’s New in Diabetes Care: Key Changes from the ADA 2024 Standards of Care

By MedXY 09/07/2025

A clinician-friendly summary of the American Diabetes Association’s 2024 Standards: who to screen, modern use of GLP‑1/GIP agents and SGLT2 inhibitors, continuous glucose monitoring, weight-management drugs, and implications for practice.

Diabetes & Endocrinology Specialties

What’s New in Diabetes Care 2024: Key Recommendations from the ADA Standards of Care

By MedXY 08/22/2025

A practical, clinician-friendly summary of the American Diabetes Association’s 2024 Standards of Care, highlighting new recommendations on GLP-1/GIP therapy, SGLT2 inhibitors, continuous glucose monitoring, and individualized care.

Diabetes & Endocrinology Specialties

ADA Standards of Care 2024: A Clinician-Friendly Guide to the New Cardiorenal‑Metabolic Era in Diabetes Care

By MedXY 08/22/2025

The ADA's 2024 Standards refocus diabetes care around cardiorenal protection, expanded use of GLP‑1 and SGLT2 therapies, wider adoption of glucose‑sensing technology, and integrated obesity management.